Volume 24 Issue 6
Jun.  2026
Turn off MathJax
Article Contents
ZHANG Rui, WU Tao, MAO Dongfeng, ZHOU Rui, LI Yunyun, GAO Mingmin, WANG Xiangli, LIU Yang. A case report and literature review of Waldenström macroglobulinemia with pleural effusion[J]. Chinese Journal of General Practice, 2026, 24(6): 1075-1077. doi: 10.16766/j.cnki.issn.1674-4152.004557
Citation: ZHANG Rui, WU Tao, MAO Dongfeng, ZHOU Rui, LI Yunyun, GAO Mingmin, WANG Xiangli, LIU Yang. A case report and literature review of Waldenström macroglobulinemia with pleural effusion[J]. Chinese Journal of General Practice, 2026, 24(6): 1075-1077. doi: 10.16766/j.cnki.issn.1674-4152.004557

A case report and literature review of Waldenström macroglobulinemia with pleural effusion

doi: 10.16766/j.cnki.issn.1674-4152.004557
Funds:

 21JR7RA015

 2021yxky078

 22YF7FA106

 23JRRA1674

 25JRRA1184

  • Received Date: 2025-02-19
    Available Online: 2026-11-10
  • This study reports a rare case of Waldenström's macroglobulinemia (WM) in a patient presenting with dyspnea and subxiphoid distending pain as the primary symptoms. A retrospective analysis of the clinical data was conducted alongside a comprehensive literature review to delineate the clinical manifestations, pathological characteristics, and diagnostic challenges associated with WM. The patient was diagnosed through a multifaceted approach, including bone marrow aspiration, histopathological examination of lymph node lesions, immunofixation electrophoresis, and flow cytometry of pleural effusion. Following a therapeutic regimen of Rituximab combined with Zanubrutinib, the patient's pleural effusion significantly decreased, and the clinical condition stabilized. This case emphasizes the clinical heterogeneity of WM and underscores the necessity for clinicians to employ integrated diagnostic techniques to reduce misdiagnosis and delayed diagnosis of this malignancy.

     

  • loading
  • [1]
    中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会, 中国华氏巨球蛋白血症工作组. 淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国指南(2022年版)[J]. 中华血液学杂志, 2022, 43(8): 624-630.

    Hematology Oncology Committee of China Anti-Cancer Association, Chinese Society of Hematology, Chinese Medical Association, Chinese Working Group of Walderström Macroglobulinemia. Chinese guideline for diagnosis and treatment of lymphoplasmacytic lymphoma/Walderström macroglobulinemia (2022)[J]. Chinese Journal of Hematology, 2022, 43(8): 624-630.
    [2]
    GERTZ M A. Waldenstr m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2023, 98(2): 348-358. doi: 10.1002/ajh.26796
    [3]
    陈菲萌, 乔淑凯, 郭晓楠. 浆细胞白血病的临床特征及诊治进展[J]. 白血病·淋巴瘤, 2022, 31(6): 381-384.

    Chen F M, Qiao S K, Guo X N. Clinical characteristics of plasma cell leukemia and progress in its diagnosis and treatment[J]. Journal of Leukemia and Lymphoma, 2022, 31(6): 381-384.
    [4]
    GERTZ M A. Waldenstr m Macroglobulinemia: 2025 update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2025, 100(6): 1061-1071. doi: 10.1002/ajh.27666
    [5]
    易树华, 熊文婕, 曹欣欣, 等. 中国华氏巨球蛋白血症诊断与治疗现状调查: 一项横断面研究[J]. 中华血液学杂志, 2024, 45(2): 148-155.

    Yi S H, Xiong W J, Cao X X, et al. Diagnosis and treatment understanding of Waldenstr?m macroglobulinemia in China: a cross-sectional study[J]. Chinese Journal of Hematology, 2024, 45(2): 148-155.
    [6]
    张婷, 黄俊霞, 高燕, 等. 单克隆IgM升高的B细胞/浆细胞肿瘤3例报告及文献复习[J]. 青岛大学学报(医学版), 2021, 57(3): 459-462.

    Zhang T, Huang J X, Gao Y, et al. B-CELL/PLASMA cell tumor with elewated monoclonal IgM: a report of three cases and literature review[J]. Acta Aacademiae Medicinae Qingdao Universitatis, 2021, 57(3): 459-462.
    [7]
    YAN Y, YU Y, XIONG W, et al. Determination of MYD88 and CXCR4 mutations for clinical detection and their significance in Waldenstr m Macroglobulinemia[J]. Clin Cancer Res, 2024, 30(23): 5483-5493. doi: 10.1158/1078-0432.CCR-23-3939
    [8]
    KAISER L M, HARMS M, SAUTER D, et al. Targeting of CXCR4 by the naturally occurring CXCR4 antagonist EPI-X4 in Waldenstr m's Macroglobulinemia[J]. Cancers (Basel), 2021, 13(4): 826. DOI: 10.3390/cancers13040826.
    [9]
    MORENO D F, LÓPEZ-GUERRA M, PAZ S, et al. Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstr m macroglobulinaemia[J]. Br J Haematol, 2023, 200(2): 187-196. doi: 10.1111/bjh.18502
    [10]
    FERRANTE M, FURLAN D, ZIBELLINIi S, et al. MYD88(L265P) detection in IgM monoclonal gammopathies: methodological considerations for routine implementation[J]. Diagnostics(Basel), 2021, 11(5): 779. DOI: 10.3390/diagnostics11050779.
    [11]
    QIU L, LIN P. Lymphoplasmacytic lymphoma and Waldenstr m macroglobulinemia, a decade after the discovery of MYD88(L265P)[J]. Hum Pathol, 2025, 156: 105708. DOI: 10.1016/j.humpath.2024.105708.
    [12]
    BUSKE C, JURCZAK W, SALEM J E, et al. Managing Waldenstr m's macroglobulinemia with BTK inhibitor[J]. Leukemia, 2023, 37(1): 35-46. doi: 10.1038/s41375-022-01732-9
    [13]
    汉英, 石亚军, 吴涛. 弥漫大B细胞淋巴瘤合并淋巴浆细胞淋巴瘤/华氏巨球蛋白血症伴IgM及IgG共存的临床研究[J]. 检验医学与临床, 2024, 21(11): 1655-1659.

    Han Y, Shi Y J, Wu T. Clinical study of diffuse large B-cell lymphoma combined with lymphoplasmacytic lymphoma/Waldenstr?m macroglobulinemia with biclclonic IgM and IgG[J]. Laboratory Medicine and Clinic, 2024, 21(11): 1655-1659.
    [14]
    GERTZ M A. Waldenstr m macroglobulinemia: 2021 update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2021, 96(2): 258-269. doi: 10.1002/ajh.26082
    [15]
    刘亚宁, 李焱, 任利涛, 等. 苯达莫司汀联合R-CHOP方案对弥漫大B细胞淋巴瘤疗效及安全性的影响[J]. 中华全科医学, 2024, 22(7): 1150-1153. doi: 10.16766/j.cnki.issn.1674-4152.003587

    Liu Y N, Li Y, Ren L T, et al. Effects of bendamustine combined with R-CHOP on the efficacy and safety of diffuse large B-cell lymphoma[J]. Chinese Journal of General Practice, 2024, 22(7): 1150-1153. doi: 10.16766/j.cnki.issn.1674-4152.003587
    [16]
    CHAN W L, CHONG V C L, WEE I J Y, et al. Efficacy and safety of front-line treatment regimens for Waldenstr m macroglobulinaemia: a systematic review and meta-analysis[J]. Blood Cancer J, 2023, 13(1): 140. DOI: 10.1038/s41408-023-00916-5.
    [17]
    TREON S P, SAROSIEK S, CASTILLO J J. How I use genomics and BTK inhibitors in the treatment of Waldenstr m macroglobulinemia[J]. Blood, 2024, 143(17): 1702-1712. doi: 10.1182/blood.2022017235
    [18]
    LU R M, HWANG Y C, LIU I J, et al. Development of therapeutic antibodies for the treatment of diseases[J]. J BIOMED SCI, 2020, 27(1): 1-30.
    [19]
    PEREZ DE ACHA O, REIMAN L, JAYABALAN D S, et al. CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies[J]. Blood Adv, 2023, 7(21): 6430-6440. doi: 10.1182/bloodadvances.2023010162

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (9) PDF downloads(1) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return